318 related articles for article (PubMed ID: 7905785)
1. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
3. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
4. Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells.
Li SR; Koller E; Valent P; Gludovacz D; Yang Q; Patri P; Angelberger P; Dudczak R; Virgolini I
Life Sci; 2001 Feb; 68(11):1243-57. PubMed ID: 11233992
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
6. Lack of evidence for cross-competition between vasoactive intestinal peptide and somatostatin at their respective receptors.
Hannon JP; Langenegger D; Waser B; Hoyer D; Reubi JC
Eur J Pharmacol; 2001 Aug; 426(3):165-73. PubMed ID: 11527540
[TBL] [Abstract][Full Text] [Related]
7. Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig.
Dupont C; Broyart JP; Broer Y; Chenut B; Laburthe M; Rosselin G
J Clin Invest; 1981 Mar; 67(3):742-52. PubMed ID: 6259209
[TBL] [Abstract][Full Text] [Related]
8. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
9. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
10. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone (PTH) and PTH-related peptide induce relaxation of smooth muscle cells from guinea pig ileum: interaction with vasoactive intestinal peptide receptors.
Botella A; Rekik M; Delvaux M; Davicco MJ; Barlet JP; Frexinos J; Bueno L
Endocrinology; 1994 Nov; 135(5):2160-7. PubMed ID: 7525262
[TBL] [Abstract][Full Text] [Related]
13. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
14. Characterization of somatostatin receptors on human neuroblastoma tumors.
O'Dorisio MS; Chen F; O'Dorisio TM; Wray D; Qualman SJ
Cell Growth Differ; 1994 Jan; 5(1):1-8. PubMed ID: 8123588
[TBL] [Abstract][Full Text] [Related]
15. [Vasoactive intestinal peptide receptor in a human pancreatic carcinoma cell line].
Chen Y
Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):135-7, 12. PubMed ID: 2163737
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
Reubi JC; Waser B; Laissue JA; Gebbers JO
Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
[TBL] [Abstract][Full Text] [Related]
17. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
[TBL] [Abstract][Full Text] [Related]
18. The development of VIP-ellipticine conjugates.
Moody TW; Czerwinski G; Tarasova NI; Moody DL; Michejda CJ
Regul Pept; 2004 Dec; 123(1-3):187-92. PubMed ID: 15518911
[TBL] [Abstract][Full Text] [Related]
19. Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors.
Xia M; Gaufo GO; Wang Q; Sreedharan SP; Goetzl EJ
J Immunol; 1996 Aug; 157(3):1132-8. PubMed ID: 8757618
[TBL] [Abstract][Full Text] [Related]
20. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Smith-Jones PM; Bischof C; Leimer M; Gludovacz D; Angelberger P; Pangerl T; Peck-Radosavljevic M; Hamilton G; Kaserer K; Kofler A; Schlangbauer-Wadl H; Traub T; Virgolini I
Endocrinology; 1999 Nov; 140(11):5136-48. PubMed ID: 10537142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
